Pharmacare News Bulletins

Nova Scotia Pharmacare

Pharmacare News Bulletins

The Pharmacare News Bulletins, which are mailed to pharmacies and physicians, are listed below. They are an important source of information as they provide timely information on recent changes to the Pharmacare Programs.

Please continue to refer to the Pharmacare News Bulletins to stay current with Formulary and Pharmacare Program updates.

Latest Issues

October Bulletin Vol. 21 – 09
Public Funding of Assessment and Prescribing for Lyme Disease Chemoprophylaxis; Seasonal Influenza Vaccinations Administered by Other Health Care Providers; New Exception Status Benefit: Xospata (gilteritinib)

September Bulletin Vol. 21 – 08
Nova Scotia Formulary Updates Administration of Publicly-Funded Influenza Vaccine by Pharmacies for the 2021-2022 Influenza Season

August Bulletin Vol. 21 – 07
New Exception Status Benefits: Prevymis (letermovir), Takhzyro (lanadelumab)

June Bulletin Vol. 21 – 06
Changes to Reimbursement of Blood Glucose Test Strips
Criteria Update: Brenzys (etanercept)
Updates to the Nova Scotia Pharmacy Guide
Payment Statement Distribution

May Bulletin Vol. 21 – 05 (PDF)
New Exception Status Benefits: Kanuma (sebelipase alfa), Lonsurf (trifluridine/tipiracil), Nubeqa (darolutamide), Onpattro (patisiran)

April Bulletin Vol. 21 – 04 (PDF)
COVID-19 Immunizations

March 21 – 03 (PDF)
Virtual Care Update, New Exception Status Benefit: Truxima (rituximab)

March 21–02 (PDF)
New Exception Status Benefits: Vigamox and generic brands

January 21-01 (PDF)
New Exception Status Benefits: pdp-Amlodipine, Cystadrops (cysteamine)

Latest Issue

August Bulletin Vol. 21 – 06
New Exception Status Benefits: Prevymis (letermovir), Takhzyro (lanadelumab)

June Bulletin Vol. 21 – 05
Criteria Update: Brenzys (etanercept)

May Bulletin Vol. 21 – 04
New Exception Status Benefits: Kanuma (sebelipase alfa), Lonsurf (trifluridine/tipiracil), Nubeqa (darolutamide), Onpattro (patisiran)

March Bulletin Vol. 21 – 03
New Exception Status Benefit: Truxima (rituximab) Criteria Updates: Lyrica and generic brands (pregabalin), Neurontin and generic brands (gabapentin), Myrbetriq (mirabegron)

March Bulletin Vol. 21 – 02
New Exception Status Benefits: Vigamox and generic brands (moxifloxacin), Zymar and generic brands (gatifloxacin)

January Bulletin Vol. 21 – 01
New Exception Status Benefits: pdp-Amlodipine, Cystadrops (cysteamine)